The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Outlook Therapeutics Inc. (OTLK) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0001, or -0.01%, to $1.0999. The Outlook Therapeutics Inc. has recorded 3,344 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence.
Outlook Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $1.10 and fluctuated between $1.1300 as its day high and $1.0800 as its day low. The current market capitalization of Outlook Therapeutics Inc. is $276.31M. A total of 0.83 million shares were traded on the day, compared to an average of 503.88K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, OTLK has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 14,230,418 and the disposition of 0 shares. Over the last 12 months, there were 19 BUYs and 2 SELLs from insiders. Insiders purchased 73,238,744 shares during that period but sold 30,482,529.
In the most recent transaction, Evanson Jeff sold 103,255 shares of OTLK for 1.22 per share on Jan 19. After the transaction, the Chief Commercial Officer now owns 1,012,975 company shares. In a previous transaction on Jan 18, Evanson Jeff sold 33,738 shares at 1.25 per share. OTLK shares that Chief Commercial Officer owns now total 1,116,230.
Among the insiders who sold shares, Evanson Jeff disposed of 27,162 shares on Jan 17 at a per-share price of $1.31. This resulted in the Chief Commercial Officer holding 1,149,968 shares of OTLK after the transaction. In another insider transaction, Sukhtian Faisal Ghiath bought 30,000 shares at $1.29 per share on Oct 07. Company shares held by the Director now total 68,000.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for OTLK in the last 3 months, the mean price target is $6.75 with high estimates of $10.00 and low estimates of $5.00. In terms of 52-week highs and lows, OTLK has a high of $2.12 and a low of $0.68.
As of this writing, OTLK has an earnings estimate of -$0.07 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.07 per share and a lower estimate of -$0.08. The company reported an EPS of -$0.09 in the last quarter, which was -50.00% lower than expectations of -$0.06.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OTLK is Buy with a score of 5.00. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.